GlassScriptPhysician profile
David Michael Kranc
NPI 1649267790
$2,020.71
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $49.92 · 2021: $538 · 2022: $378 · 2023: $533 · 2024: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $435.11 | 2019-2024 | Lumenis Pulse 120h, Spaceoar Vue System - 10ml, Greenlight Xps |
| Astellas Pharma US INC | $314.29 | 2019-2024 | Myrbetriq, Veozah |
| Coloplast Corp | $203.58 | 2020-2024 | Titan, Speedicath |
| Sumitomo Pharma America, INC. | $141.89 | 2023-2024 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $114.63 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $107.03 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $77.15 | 2021-2022 | |
| 180 Medical, INC. | $70.07 | 2019-2022 | |
| Tolmar, INC. | $63.04 | 2023-2024 | |
| Pfizer INC. | $62.87 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $48.99 | 2024 | Adstiladrin |
| Dentsply Ih Ab | $48.12 | 2022-2023 | Lofric |
| Medtronic, INC. | $45.34 | 2022-2023 | Interstim |
| Myriad Genetic Laboratories, INC. | $39.33 | 2023 | Prolaris |
| Teleflex LLC | $35.73 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $34.21 | 2023-2024 | Axonics |
| Procept Biorobotics Corporation | $34.08 | 2023 | Aquabeam Robotic System |
| Blue Earth Diagnostics | $25.03 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $22.18 | 2019 | |
| Abbvie INC. | $21.59 | 2019 | |
| Urovant Sciences INC | $21.47 | 2022 | |
| Allergan, INC. | $20.41 | 2021 | |
| Antares Pharma, INC. | $16.97 | 2020 | |
| Janssen Biotech, INC. | $13.80 | 2019 | |
| Travere Therapeutics, INC. | $3.80 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kranc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.